Bromocriptine Capsules and Menactra Intramuscular

• Generic Name: bromocriptine
• Dosage Forms: capsule
• Other Brand Names: Parlodel, Cycloset

This medication guide provides information about the Parlodel brand of bromocriptine. Cycloset is another brand of bromocriptine that is not covered in this medication guide.

The Parlodel brand of bromocriptine is used to treat certain conditions caused by a hormone imbalance in which there is too much prolactin in the blood (hyperprolactinemia). Symptoms include lack of sexual development in adolescents. Women may have missed menstrual periods, loss of interest in sex, hot flashes, infertility, or unexpected breast milk production and leakage from the nipples. Men may have enlarged breasts, decreased libido, decreased facial or body hair, and loss of muscle. Parlodel is also used to treat these disorders when they are caused by brain tumors that can produce prolactin.

Parlodel is sometimes used together with surgery or radiation in treating acromegaly, a condition caused by a pituitary gland tumor that produces too much growth hormone. Parlodel is also used to treat symptoms of Parkinson's disease, such as stiffness, tremors, muscle spasms, and poor muscle control.

Bromocriptine may also be used for purposes not listed in this medication guide.

• Generic Name: meningococcal conjugate vaccine
• Dosage Forms: n.a.
• Other Brand Names: Menactra, Menveo

Meningococcal polysaccharide diphtheria conjugate vaccine is an active immunizing agent used to prevent infection by certain groups of meningococcal bacteria. The vaccine works by causing your body to produce its own protection (antibodies) against the bacteria.

The following information applies only to the meningococcal vaccine used for meningococcal bacteria Groups A, C, Y, and W-135. These groups cause nearly all of the meningococcal meningitis cases in the U.S. The vaccine will not protect against infection caused by other meningococcal bacteria groups, such as Group B.

Meningococcal infection can cause life-threatening illnesses, such as meningococcal meningitis, which affects the brain, and meningococcemia, which affects the blood. Some persons with meningococcal meningitis and/or meningococcemia may die. The rate of these diseases peak in adolescence and early adulthood and are more likely to occur in persons with certain diseases or conditions that make them more susceptible to a meningococcal infection or more likely to develop serious problems from a meningococcal infection.

Immunization against meningococcal disease is recommended for persons who are at risk of getting the disease because:

• They have certain diseases or conditions that make them more susceptible to a meningococcal infection or more likely to develop serious problems from a meningococcal infection.
• They are living in, working in, or visiting an area where there is a strong possibility of contracting meningococcal disease.

Menveo® is recommended for use in children 2 months of age and older and adults younger than 55 years of age. Menactra® is recommended for use in children 9 months of age and older and adults younger than 55 years of age.

This vaccine is to be administered only by or under the supervision of your doctor.